Literature DB >> 33392432

Coagulopathy in elderly patients with coronavirus disease 2019.

Xueting Yuan1, Xunliang Tong2, Yan Wang2, He Wang2, Liuming Wang3, Xiaomao Xu1,2.   

Abstract

BACKGROUND: Since the outbreak of coronavirus disease 2019 (COVID-19), clinical features have been analyzed in detail. However, coagulopathy in elderly COVID-19 patients has been scarcely reported.
METHODS: Coagulation parameters of 189 patients with COVID-19 in Tongji hospital were retrospectively analyzed among age groups.
RESULTS: Patients were divided into 2 groups: older group (≥65 years, n = 87) and younger group (<65 years, n = 102). The proportion of patients with elevated fibrinogen (79.0% vs 59.6%, p = .005) and D-dimer (78.0% vs 55.2%, p = .001) shows the significant difference between the groups. The elderly patients revealed significantly longer prothrombin time (14.0 [13.4-14.4]s vs 13.6 [13.2-14.1]s, p = .026), higher D-dimer (1.00 [0.5-1.9] μg/mL vs 0.6 [0.3-1.6] μg/mL, p = .013) and fibrinogen (5.2 [4.1-6.2] g/L vs 4.4 [3.4-5.7] g/L, p = .004) levels, compared to the younger group. A positive correlation was observed between the coagulation parameters and inflammatory markers including high-sensitivity C-reactive protein and interleukin-6 (p < .05).
CONCLUSIONS: The hypercoagulable state is more common in elderly COVID-19 patients, and coagulopathy is associated with excessive systemic inflammation.
© 2020 The Authors. Aging Medicine published by Beijing Hospital and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  COVID‐19; aged; blood coagulation disorders; inflammation

Year:  2020        PMID: 33392432      PMCID: PMC7771561          DOI: 10.1002/agm2.12133

Source DB:  PubMed          Journal:  Aging Med (Milton)        ISSN: 2475-0360


  28 in total

Review 1.  Coagulation and innate immune responses: can we view them separately?

Authors:  Mieke Delvaeye; Edward M Conway
Journal:  Blood       Date:  2009-07-07       Impact factor: 22.113

2.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

Review 3.  Inflammation, endothelium, and coagulation in sepsis.

Authors:  Marcel Schouten; Willem Joost Wiersinga; Marcel Levi; Tom van der Poll
Journal:  J Leukoc Biol       Date:  2007-11-21       Impact factor: 4.962

4.  Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.

Authors:  S Kritas; P Conti; G Ronconi; A Caraffa; C Gallenga; R Ross; I Frydas
Journal:  J Biol Regul Homeost Agents       Date:  2020 March-April,       Impact factor: 1.711

5.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.

Authors:  Ning Tang; Huan Bai; Xing Chen; Jiale Gong; Dengju Li; Ziyong Sun
Journal:  J Thromb Haemost       Date:  2020-04-27       Impact factor: 5.824

6.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

Review 7.  Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.

Authors:  Mehmet Soy; Gökhan Keser; Pamir Atagündüz; Fehmi Tabak; Işık Atagündüz; Servet Kayhan
Journal:  Clin Rheumatol       Date:  2020-05-30       Impact factor: 2.980

8.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

9.  Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.

Authors:  C K Wong; C W K Lam; A K L Wu; W K Ip; N L S Lee; I H S Chan; L C W Lit; D S C Hui; M H M Chan; S S C Chung; J J Y Sung
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

10.  [Consensus of Chinese experts on diagnosis of disseminated intravascular coagulation (version 2017)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-05-14
View more
  3 in total

1.  Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study.

Authors:  Muhammad Fachri; Mochammad Hatta; Sefia Nabila Nur Azmi Tarigan; Risky Akaputra; Ressy Dwiyanti; Ahmad Syukri; Ade Rifka Junita; Muhammad Reza Primaguna; Andini Febrianty
Journal:  Ann Med Surg (Lond)       Date:  2022-06-28

Review 2.  Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework.

Authors:  Laure-Alix Clerbaux; Maria Cristina Albertini; Núria Amigó; Anna Beronius; Gillina F G Bezemer; Sandra Coecke; Evangelos P Daskalopoulos; Giusy Del Giudice; Dario Greco; Lucia Grenga; Alberto Mantovani; Amalia Muñoz; Elma Omeragic; Nikolaos Parissis; Mauro Petrillo; Laura A Saarimäki; Helena Soares; Kristie Sullivan; Brigitte Landesmann
Journal:  J Clin Med       Date:  2022-07-31       Impact factor: 4.964

3.  Elevated Levels of Pleiotropic Interleukin-6 (IL-6) and Interleukin-10 (IL-10) are Critically Involved With the Severity and Mortality of COVID-19: An Updated Longitudinal Meta-Analysis and Systematic Review on 147 Studies.

Authors:  Sarah Jafrin; Md Abdul Aziz; Mohammad Safiqul Islam
Journal:  Biomark Insights       Date:  2022-06-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.